GlassScriptPhysician profile
Claire B Price
NPI 1841262730
$3,080.48
in general payments reported to CMS, 2019-2025
17 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $84.10 · 2021: $174 · 2022: $460 · 2023: $274 · 2024: $573 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.87 | 2022-2025 | |
| Biotissue Holdings INC. | $463.98 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $310.65 | 2019-2025 | |
| Allergan, INC. | $294.50 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $228.33 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $184.60 | 2020-2025 | |
| Oyster Point Pharma, INC. | $150.96 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $96.12 | 2019-2020 | |
| Alcon Vision LLC | $89.85 | 2021-2025 | Tryptyr, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $56.30 | 2019-2023 | Tecnis Iol |
| Optos, INC. | $54.25 | 2019-2020 | |
| Rxsight INC | $44.92 | 2024-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $27.48 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $21.83 | 2022 | |
| Harrow Eye, LLC | $18.46 | 2025 | Vevye |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14.11 | 2023 | Tepezza |
| Omeros Corporation | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.